Cargando…

Advances in gene therapy for muscular dystrophies

Duchenne muscular dystrophy (DMD) is a recessive lethal inherited muscular dystrophy caused by mutations in the gene encoding dystrophin, a protein required for muscle fibre integrity. So far, many approaches have been tested from the traditional gene addition to newer advanced approaches based on m...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdul-Razak, Hayder, Malerba, Alberto, Dickson, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991540/
https://www.ncbi.nlm.nih.gov/pubmed/27594988
http://dx.doi.org/10.12688/f1000research.8735.1
_version_ 1782448878527709184
author Abdul-Razak, Hayder
Malerba, Alberto
Dickson, George
author_facet Abdul-Razak, Hayder
Malerba, Alberto
Dickson, George
author_sort Abdul-Razak, Hayder
collection PubMed
description Duchenne muscular dystrophy (DMD) is a recessive lethal inherited muscular dystrophy caused by mutations in the gene encoding dystrophin, a protein required for muscle fibre integrity. So far, many approaches have been tested from the traditional gene addition to newer advanced approaches based on manipulation of the cellular machinery either at the gene transcription, mRNA processing or translation levels. Unfortunately, despite all these efforts, no efficient treatments for DMD are currently available. In this review, we highlight the most advanced therapeutic strategies under investigation as potential DMD treatments.
format Online
Article
Text
id pubmed-4991540
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher F1000Research
record_format MEDLINE/PubMed
spelling pubmed-49915402016-09-01 Advances in gene therapy for muscular dystrophies Abdul-Razak, Hayder Malerba, Alberto Dickson, George F1000Res Review Duchenne muscular dystrophy (DMD) is a recessive lethal inherited muscular dystrophy caused by mutations in the gene encoding dystrophin, a protein required for muscle fibre integrity. So far, many approaches have been tested from the traditional gene addition to newer advanced approaches based on manipulation of the cellular machinery either at the gene transcription, mRNA processing or translation levels. Unfortunately, despite all these efforts, no efficient treatments for DMD are currently available. In this review, we highlight the most advanced therapeutic strategies under investigation as potential DMD treatments. F1000Research 2016-08-18 /pmc/articles/PMC4991540/ /pubmed/27594988 http://dx.doi.org/10.12688/f1000research.8735.1 Text en Copyright: © 2016 Abdul-Razak H et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Abdul-Razak, Hayder
Malerba, Alberto
Dickson, George
Advances in gene therapy for muscular dystrophies
title Advances in gene therapy for muscular dystrophies
title_full Advances in gene therapy for muscular dystrophies
title_fullStr Advances in gene therapy for muscular dystrophies
title_full_unstemmed Advances in gene therapy for muscular dystrophies
title_short Advances in gene therapy for muscular dystrophies
title_sort advances in gene therapy for muscular dystrophies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991540/
https://www.ncbi.nlm.nih.gov/pubmed/27594988
http://dx.doi.org/10.12688/f1000research.8735.1
work_keys_str_mv AT abdulrazakhayder advancesingenetherapyformusculardystrophies
AT malerbaalberto advancesingenetherapyformusculardystrophies
AT dicksongeorge advancesingenetherapyformusculardystrophies